Nexstim Plc · OMXHEX:NXTMH
Nexstim — Shareholder Meeting (March 2017)
18 slides from Nexstim's shareholder meeting presentation, Mar 28, 2017
Slide 1: Targeting a paradigm shift in stroke rehabilitation
Targeting a paradigm shift in stroke rehabilitation Martin Jamieson| CEO & Chairman of the Board | Nexstim Corporate Presentation, AGM 28 March 2017 @NexstimOyj
Slide 2: Important information
Important information This document and the information contained herein are being presented by Nexstim Oyj Certain of the information contained herein concerning industry and market data, economic (“Nexstim” or the “Company”). In connection with any presentation or review of this trends, market pos
Slide 3: Nexstim Transcranial Magnetic Stimulation (TMS) platform
Nexstim Transcranial Magnetic Stimulation (TMS) platform Diagnostic Therapy Navigated Brain Stimulation (NBS) Navigated Brain Therapy (NBT®) 3
Slide 4: Platform protected with 17 patent families
Platform protected with 17 patent families ● 63 granted patents, 35 pending ● Right to software: Nexstim owns rights to its NBT® and NBS Systems’ software developed in-house. ● Core algorithms kept as trade secrets 4
Slide 5: Navigated Brain Stimulation for pre-surgical mapping of motor and speech cortex
Navigated Brain Stimulation® for pre-surgical mapping of motor and speech cortex @NexstimOyj
Slide 6: NBS Pre-Surgical Mapping makes the difference to clinical outcome
NBS Pre-Surgical Mapping makes the difference to clinical outcome Progression-free Survival (Months) Direct Cortical 46% Increase in Stimulation PFS in Low Grade Gliomas1 NBS + Direct Cortical Stimulation 0 5 10 15 20 25 1 Dietmar Frey, Peter Vajkoczy, and Thomas Picht Navigated transcranial magneti
Slide 7: NBS Pre-Surgical Mapping Major Centers
NBS Pre-Surgical Mapping Major Centers 7
Slide 8: NBS Pre-Surgical Mapping US Distribution Partners
NBS Pre-Surgical Mapping US Distribution Partners Partner Partner TBD identified Partner identified Partner identified Partner identified NeuroTec JTec Surgical Partner TBD MedEx SW Surgical Solutions 8
Slide 9: Navigated Brain Therapy
Navigated Brain Therapy® @NexstimOyj
Slide 10: NBT has potential for multiple therapeutic applications due to precise navigation
NBT® (Navigated Brain Therapy) has potential for multiple therapeutic applications due to precise navigation Primary motor cortex Primary motor/sensory cortex (stroke rehabilitation therapy) (pain therapy) Dorsolateral prefrontal cortex (depression therapy) Temporoparietal cortex (therapy for audito
Slide 11: Market opportunity in stroke rehabilitation
Market opportunity in stroke rehabilitation 2015 Incidence of stroke 2015 Stroke survivors USA USA 0.8 M 6.5 M China China 15 M Europe 2.5 M (7.5 M)* Europe 1.2 M 8.0 M *Published data • Large and rapidly growing market • 50% of stroke survivors will have upper limb paralysis with few available trea
Slide 12: Clinical data comparing NBT + occupational therapy (OT) with OT
Clinical data comparing NBT® + occupational therapy (OT) with OT ● 199 patients – 12 leading US centres Phase III NICHE results >2/3 >2/3 ● Excellent results in active group Rate for clinically meaningful NBT® SHAM <1/3 ● Sham coil in control group proved active response +OT +OT OT ● Safety endorsed
Slide 13: Key performance indicators
Key performance indicators EUR in thousands H2 2016 H2 2015 FY 2016 FY 2015 Full year expenses 6 months 6 months 12 months 12 months EUR 2,546.1 thousand lower Net sales 1,590.1 1,884.7 2,482.6 2,527.9 related to Phase III multi-centre Personnel expenses -2,038.7 -2,063.8 -4,253.2 -3,969.8 trial end
Slide 14: Nexstim Funding
Nexstim Funding ● Accelerated pace in the two year funding arrangement with Bracknor Investment and Finnish Innovation Fund Sitra ● Funding arrangement is a combination of: ● EUR 5 million of convertible bonds – 100% funded ● EUR 6.5 million stand-by equity facilities ~92% funded ● EUR 0.5 million d
Slide 15: Nexstim Strategic Actions
Nexstim Strategic Actions ● Focus on therapeutic applications – Primarily Stroke, Depression and Pain Stroke Rehabilitation Therapy Chronic Pain Therapy Depression Therapy 15
Slide 16: Nexstim Strategic Actions
Nexstim Strategic Actions Timeline of US Regulatory Development for Stroke December February March April 2016 2017 2018 2018 FDA approval of Trial Expected Expected Trial Protocol Commenced Trial FDA 510(k) Completion de novo filing Rehabilitation Institute of Chicago (central site) Spaulding Rehabi
Slide 17: Nexstim Strategic Actions
Nexstim Strategic Actions ● File 510(k) for depression during H1 2017 ● Exploit CE marked approval in Stroke – EU sales to begin in H1 2017 ● Partner agreements to include major Asian territories ● Prepare funding plan for US therapy commercialisation 17
Slide 18: Thank you
Thank you @NexstimOyj